Cellectis (NASDAQ: CLLS)
|Date||Analyst Firm||Analyst Name||Action||Rating||Action Price||Prior Price||Target|
You can purchase shares of Cellectis (NASDAQ: CLLS) through any online brokerage.
The latest price target for Cellectis (NASDAQ: CLLS) was reported by Goldman Sachs on Tuesday, May 24, 2022. The analyst firm set a price target for 2.00 expecting CLLS to fall to within 12 months (a possible -27.27% downside). 6 analyst firms have reported ratings in the last year.
The stock price for Cellectis (NASDAQ: CLLS) is $2.75 last updated July 6, 2022, 8:00 PM UTC.
There are no upcoming dividends for Cellectis.
Cellectis’s Q2 earnings are confirmed for Thursday, August 4, 2022.
There is no upcoming split for Cellectis.
Cellectis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.